发明名称 Pharmaceutical composition for treatment of eye pain, containing PGE2 synthesis inhibitor
摘要 The present invention relates to a pharmaceutical composition for the treatment of eye pain, containing a PGE2 synthesis inhibitor. The use of the pharmaceutical composition for the prevention or treatment of eye pain according to the present invention, which contains the PGE2 synthesis inhibitor as an active ingredient, makes it possible to alleviate the symptoms of eye pain by selectively inhibiting the PGE2 expression level, and also has the advantages of treating and preventing xerophthalmia and of overcoming and preventing eye discomfort caused by various inflammation-inducing circumstances including following surgery. Also, by using a kit for detecting the amount of PGE2, PGD2 and COX2, the present invention makes it possible to easily diagnose eye-pain symptoms in clinical practice, and can be widely used in checking the state not only of patients having xerophthalmia but also patients following eye surgery.
申请公布号 US9629855(B2) 申请公布日期 2017.04.25
申请号 US201214648970 申请日期 2012.12.27
申请人 INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY 发明人 Lee Hyung Keun;Shim Jong Woo
分类号 A61K38/00;A61P9/10;A61P27/02;A61K31/635;A61K9/00;A61K31/557;A61K31/192;A61K31/18;A61K38/06;A61K31/405;A61K31/4184;A61K31/407;A61K31/5415;A61K31/015;A61K31/425;A61K31/00 主分类号 A61K38/00
代理机构 Sheridan Ross P.C. 代理人 Sheridan Ross P.C.
主权项 1. A method of preventing or treating ocular pain resulting from dry eye syndrome by administering a PGE2 synthesis inhibitor to a mammal having dry eye syndrome, wherein the PGE2 synthesis inhibitor is selected from the group consisting of 15-deoxy-Δ12,14-PGJ2, Exisulind, Leukotriene C4, mk-886, Naphthalene disulphonamide, and γ-hydroxybutenolide.
地址 KR
您可能感兴趣的专利